- Home
- CVKD vs ANTX Comparison
CVKD vs ANTX Comparison
Compare CVKD & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- ANTX
- Stock Information
- Founded
- CVKD 2022
- ANTX 2017
- Country
- CVKD United States
- ANTX United States
- Employees
- CVKD N/A
- ANTX N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- ANTX Health Care
- Exchange
- CVKD Nasdaq
- ANTX Nasdaq
- Market Cap
- CVKD 29.5M
- ANTX 33.2M
- IPO Year
- CVKD 2023
- ANTX 2022
- Fundamental
- Price
- CVKD $11.37
- ANTX $1.09
- Analyst Decision
- CVKD Strong Buy
- ANTX Buy
- Analyst Count
- CVKD 1
- ANTX 2
- Target Price
- CVKD $32.00
- ANTX $2.00
- AVG Volume (30 Days)
- CVKD 37.2K
- ANTX 92.7K
- Earning Date
- CVKD 08-06-2025
- ANTX 08-12-2025
- Dividend Yield
- CVKD N/A
- ANTX N/A
- EPS Growth
- CVKD N/A
- ANTX N/A
- EPS
- CVKD N/A
- ANTX N/A
- Revenue
- CVKD N/A
- ANTX N/A
- Revenue This Year
- CVKD N/A
- ANTX N/A
- Revenue Next Year
- CVKD N/A
- ANTX N/A
- P/E Ratio
- CVKD N/A
- ANTX N/A
- Revenue Growth
- CVKD N/A
- ANTX N/A
- 52 Week Low
- CVKD $5.70
- ANTX $0.87
- 52 Week High
- CVKD $22.90
- ANTX $2.98
- Technical
- Relative Strength Index (RSI)
- CVKD 39.88
- ANTX 52.20
- Support Level
- CVKD $11.15
- ANTX $1.05
- Resistance Level
- CVKD $12.26
- ANTX $1.10
- Average True Range (ATR)
- CVKD 1.07
- ANTX 0.03
- MACD
- CVKD 0.01
- ANTX 0.01
- Stochastic Oscillator
- CVKD 13.68
- ANTX 83.50
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.